Ivermectin Combined With Immune Checkpoint Inhibition in Cancer (ICONIC) (NCT07487805) (2026)

Government Record · University of Florida · October 13, 2026

University of Florida, 2026-10-13: Registered phase II randomized trial (80 patients, adult solid tumors) of intermediate- versus high-dose ivermectin added to standard immune checkpoint inhibitor therapy; not yet recruiting, with a T-cell pharmacodynamic primary endpoint.

Subjects on this arm will take 400 µg/kg of ivermectin orally from Day 1 through 3 weekly for 4 weeks while undergoing their standard immune checkpoint inhibitor treatment.

University of Florida, 2026-10-13: Registered phase II randomized trial (80 patients, adult solid tumors) of intermediate- versus high-dose ivermectin added to standard immune checkpoint inhibitor therapy; not yet recruiting, with a T-cell pharmacodynamic primary endpoint. C1 record field (transcribed from the API JSON). Phase 2, interventional, estimated enrollment 80, estimated start 2026-12, primary completion 2027-09. Arms: ivermectin 200 ug/kg vs 400 ug/kg PO days 1-3 weekly for 4 weeks. Primary outcome: change in Ki-67+HLA-DR+ non-naive CD8 T-cells (no clinical efficacy endpoint among primary outcomes). Registered, no results. The record's own background states 'clinical data remain virtually absent' and cites the Loja, Ecuador 2023 survey (19% using ivermectin as an adjunct to cancer treatment). Registry entry; no results posted. Study type: regulatory record.